Clinical Trial Update: Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of sorafenib and omacetaxine mepesuccinate in newly diagnosed or relapsed/refractory acute myeloid leukemia with FLT3…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Omacetaxine mepesuccinate (homoharringtonine)
• Sorafenib (Sorafenib)

Snippet

Sponsor: The University of Hong Kong | Conditions: AML, FLT3-ITD Mutation | Phase 2 | Status: COMPLETED